Steven Grover: Germline Heterozygous Loss of Function in FXII is Associated with a Significantly Reduced Risk of Venous Thromboembolism
Steven Grover, Staff Scientist II at Beth Israel Deaconess Medical Center, shared on LinkedIn:
“Evidence for a role of coagulation factor FXII in the pathogenesis of venous thromboembolism has proven elusive to date. In work led by Amelia Haj from Tem Bendapudi‘s group we show that germline heterozygous loss of function in FXII is associated with a significantly reduced risk of venous thromboembolism. A 50% reduction in plasma FXII levels, although unremarkable in the classical activated partial thromboplastin time assay, is sufficient to significantly reduce plasma thrombin generation by calibrated automated thrombography and venous thrombosis in a preclinical model.
Delighted to have been involved in this important work alongside several researchers from the Blood Research Center at UNC, Beth Israel Deaconess Medical Center and Massachusetts General Hospital.”
Title: Coagulation factor XII haploinsufficiency is protective against venous thromboembolism in a population-scale multidimensional analysis
Authors: Amelia K. Haj, David S. Paul, Sean J. Jurgens, Harish Eswaran, Lu-Chen Weng, Justine Ryu, Alfonso Rodriguez Espada, Sharjeel Chaudhry, Louis M. Feingold, Kristen Burke, Satoshi Koyama, Xin Wang, Joyce Francis, Seung Hoan Choi, Nigel Mackman, Wolfgang Bergmeier, Alex Burgin, Joel T. Rämö, Patrick T. Ellinor, Steven P. Grover & Pavan K. Bendapudi
The paper is out now in Springer Nature journal Nature Communications, read it here.
Stay informed with Hemostasis Today.
-
Nov 2, 2025, 14:172019 ESC/EAS Guidelines for the Management of Dyslipidaemias Discussion with Lale Tokgözoğlu and Jeanine Roeters van Lennep
-
Nov 2, 2025, 14:14Nihar Desai: Post-Transplant Dysphagia
-
Nov 2, 2025, 14:13Zia Choudhry Launchs a New Digital Education Platform Designed to Inform and Empower People Living With wAIHA
-
Nov 2, 2025, 14:13Rahul Bhargava: Landmark Study Shows Excellent Outcomes in Pediatric AML Transplant
-
Nov 2, 2025, 10:17ESO: Register for the Live WSC 2025 Highlights Webinar
-
Nov 2, 2025, 14:21Claude Franceschi: I Advise You to Understand the Hemodynamic Pathophysiology of Venous Diseases Rather than Blindly Applying Ablation Techniques or Venous Stent Placement
-
Nov 2, 2025, 14:15Krishna Aragam: Why are (DCM) and Heart Failure About Twice as Common in Individuals of Self-Identified Black Race?
-
Nov 2, 2025, 14:15Raul Santos: Waist-to-Height Ratio and Coronary Artery Calcium Incidence
-
Nov 2, 2025, 14:12Steven AR Murphy: Urolithin A Shows Immune Rejuvenation and Mitochondrial Benefits in New Trial
-
Nov 2, 2025, 10:31Cihan Ay and RIETE Investigators Team Present External Validation of the VTE-PREDICT Score
-
Oct 29, 2025, 07:31The Use of Artificial Intelligence to Improve Detection of Acute Incidental Pulmonary Emboli - JTH
-
Oct 29, 2025, 07:05Shrinidhi Nathany: AI in Diagnostic Medicine
-
Oct 28, 2025, 07:02Aya Berman: AI Model for Predicting Bacteremia
-
Oct 28, 2025, 06:55The New Era of Genomics, AI and Cell Therapy in Hematology and Infectious Diseases
-
Oct 28, 2025, 06:49Lukas Gaats: Researchers Are Building Reproductive Organoids
-
Nov 2, 2025, 14:17Anamaria B: Your Mother Still Runs Part of Your DNA
-
Nov 2, 2025, 10:57Paul Bolaji on Launching The First Centralised Nigerian National Stroke Registry
-
Nov 2, 2025, 10:03Mark Stoffels: A Stroke Can Change Lives in an Instant, But With Timely Expert Care Recovery is Possible
-
Nov 2, 2025, 09:43Louise Bannon Celebrates Barbara Adams Krolak’s 10-Year Anniversary at ISTH
-
Nov 2, 2025, 08:06Sanam Loghavi Recognized at Inaugural Women in Hematology U.S. Focus Meeting 2025